Synced daily from ClinicalTrials.gov via AACT. Last sync: .
25 patiromer clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 12 indications (including Hyperkalemia & Hypertension) and 3,345 total planned enrollment. 5 Phase 3 patiromer trials and 9 Phase 2, 10 Phase 4 are listed. 3 patiromer clinical trials are actively recruiting at 11 U.S. sites across 9 states. Most recent activity: NCT05766839 (Dec 2030).
Where to Participate: All patiromer Trial Sites in the U.S. (11 sites across 9 states)
Every actively recruiting patiromertrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT04585542terminatedComparison of Potassium Binders in the ER
NCT04443608terminatedPatiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
NCT04142788terminatedRELieving Increasing oEdema Due to Heart Failure
NCT03087058terminatedPharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
NCT02033317terminatedAn Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
All patiromer trials (25)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
25 patiromer clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 17 are marked completed.
Are patiromer clinical trials recruiting in 2026?
Yes — 3 patiromer trials are actively recruiting in 2026, with 11 U.S. sites across 9 states. See the recruiting trials and the per-state site list further down this page.
What conditions is patiromer being studied for?
patiromer is being studied for Hyperkalemia, Hypertension, Chronic Kidney Diseases, Kidney Transplant, End Stage Renal Disease and 16 more. The trials are grouped by indication on this page.
What phase is patiromer in?
patiromer clinical trials span 10 Phase 4, 5 Phase 3, 9 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors patiromer clinical trials?
The lead sponsor across the most patiromer trials is Relypsa, Inc., with 16 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming patiromeras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.